Sprint Bioscience AB

DALLAS, Sept. 9, 2024 /PRNewswire/ -- Triple Daytime Emmy award-winning journalist, bestselling author, and leadership speaker Gaby Natale has partnered with Susan G. Komen®, the world's -leading breast cancer organization, as an ambassador. In this role, Natale will utilize her platform and personal journey through breast cancer to educate and engage diverse audiences in the fight against this deadly disease. Continue Reading Triple EMMY winner Gaby Natale announced as Susan G. Komen's Official Ambassador In 2024, Natale was diagnosed with breast cancer, undergoing multiple surgeries, chemotherapy, and radiation. Now cancer-free, she is dedicated to using her experience to advocate for early detection and to support others affected by the disease. "Together, we can pioneer a world without breast cancer" Natale said. " I am excited to join forces with Susan G. Komen and committed to using my voice to empower women, especially in diverse communities, to advocate for their health and to break barriers in health equity." Breast cancer is the most common cancer among Hispanic women in the U.S., with one in nine Hispanic/Latina women expected to be diagnosed during their lifetime. Research indicates that Hispanic women often face greater barriers to accessing screening mammograms compared to other ethnicities. To help educate and address these disparities, Natale will share her insights across Komen's social channels, including cross-promotional posts, a podcast interview, and the Komen blog. She will emphasize the theme of resilience in media interviews while advocating for timely mammograms, especially within the Hispanic community, which faces significant challenges in breast cancer outcomes. Natale will also lead the "Beauty in Resilience" campaign, which focuses on inclusive beauty and challenges outdated beauty standards. The campaign celebrates the strength and beauty of multicultural breast cancer survivors and provides crucial health education and resources. "This effort is about redefining beauty through the lens of resilience and strength and ensuring that every community has access to the information and care they need," explained Natale. "There is someone in every state, every city, every community who has been impacted by breast cancer. Hispanic and Latina women, in particular, face later-stage diagnoses and need our support," said Krissa Smith, Ph.D., vice president, education at Susan. G. Komen. "We're deeply grateful to Gaby Natale for using her platform to educate and support all communities. Together, we emphasize the life-saving importance of early detection, regular screenings, and mental health support. Health equity remains central to our mission, and while progress has been made, our work continues." As part of her ambassador role, Natale will participate in signature Komen events such as the 2024 Komen Dallas North Texas Race for the Cure and promote these events through bilingual media appearances. Susan G. Komen is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. For more information, visit komen.org or call 1-877 GO KOMEN. ABOUT GABY NATALE Gaby Natale believes in breaking barriers. And she embodies what she preaches. As the first Latina to win 3 Daytime Emmys® back-to-back (as host and executive producer of her own show), the first Hispanic author to be published by HarperCollins' Leadership division and one of the few foreign-born writers to narrate their audiobook in English, Gaby has had her own share of being "the first like her" in leadership spaces. A sought-after thought leader and motivational speaker, Gaby has shared her inspirational message in Fortune 500 corporations, the United Nations and in her own TEDx talk encouraging underrepresented minorities to pioneer and be what they cannot (yet) see in the world. Natale is among a few women in the entertainment industry who owns not only the rights to her content, but also a television studio. This unique situation has allowed her to combine her passion for media and her entrepreneurial spirit. People magazine named Natale one of 2018's "25 Most Powerful Latinas", highlighting the inspirational story of how she went from a local TV show that started out of a carpet warehouse to becoming the only Latina in US history to win triple back-to-back Daytime Emmys®. Her popularity grew even further when her first book, "The Virtuous Circle" by HarperCollins, became an instant bestseller, topping Amazon's New Releases charts in 3 different categories (Business, Inspiration and Self-Help). Natale is also the founder of AGANARmedia, a marketing company with a focus on Hispanic audiences that serves Fortune 500 companies such as Hilton Worldwide, Sprint, AT&T, eBay, Intuit and Amazon. In the digital world, she has a thriving fan base with over 52 million views on YouTube. A tireless advocate of gender and diversity issues, Natale is a frequent collaborator with nonprofits such as St. Jude Children's Research Hospital, Phenomenal Woman Action Campaign and Voto Latino. Natale has been featured in Forbes, CNN, Buzzfeed, NBC News, Univision and Latino Leaders magazine. She is the recipient of NALIP's Digital Trailblazer Award and of a GLAAD Media Award nomination for her portrayal of Latino LGBTQ youth in media. Natale holds a bachelor's in International Relations and a master's degree in Journalism from the University of San Andres and Columbia University. Prior to starting her career in television, Natale taught Communication and Journalism courses at the University of Texas. Originally from Argentina, Natale holds triple citizenship from the United States, Argentina and Italy and has lived in London (UK), Mexico, Washington DC and Buenos Aires. SOURCE AGANARmedia

Hot off its first FDA approval, Day One Biopharmaceuticals added a new early-stage programme to its oncology pipeline on Tuesday, hopping into the much-hyped antibody-drug conjugate (ADC) space. For more analysis on deals involving the modality, see Vital Signs: Tracking the new converts to ADCs.The California-based biotech licensed ex-China rights to MTX-13, a PTK7-targeting ADC, from MabCare Therapeutics. Day One will rename the candidate DAY301 and plans to start a Phase I trial in solid tumours by the first quarter of 2025.  The Chinese firm will receive $55 million upfront and is eligible for up to $1.15 billion in development, regulatory and commercial milestones, plus low-to-mid single-digit royalties.Solving PTK7Day One is betting on a less-well-known target for its first ADC. According to the company, PTK7 is a catalytically inactive transmembrane protein that is overexpressed in multiple solid tumours and underexpressed in healthy tissues.However, an ADC against the kinase has yet to find clinical success. AbbVie and Pfizer had been working together to develop a PTK7-targeting ADC, cofetuzumab pelidotin, but both pharmas binned the candidate last year.Genmab may have the only PTK7-directed ADC in the clinic. The company gained PRO1107, which is in a Phase I/II study for solid tumours, when it agreed in April to buy out ProfoundBio for $1.8 billion in cash. For more, see ViewPoints: How ProfoundBio fits into Genmab’s growth strategy.Samuel Blackman, Day One’s head of R&D, said that the company believes “the linker-payload technology embodied in DAY301 will overcome the limitations of earlier PTK7-targeted ADCs, giving us a potential first-in-class drug against a clinically-validated target.”Wednesday’s deal gives Day One its fourth cancer programme. The FDA in April approved Day One’s pan-RAF kinase inhibitor Ojemda (tovorafenib) to treat relapsed or refractory low-grade glioma with an activating BRAF alteration. The company’s pipeline also includes MEK 1/2 inhibitor pimasertib, which is in a Phase I/II trial for solid tumours with MAPK pathway aberrations, and a preclinical VRK1 inhibitor gained from Sprint Bio last year for a mere $3 million upfront.

Day One Biopharmaceuticals is letting the sun shine on the back end of its pipeline, inking a new preclinical licensing pact with Sprint Bioscience. Cruising on the midstage clinical success of a brain cancer therapy, Day One Biopharmaceuticals is using the wind at its sails to bolster the back of its pipeline with a $3 million upfront deal for Sprint Bioscience's preclinical program. The licensing pact, announced Wednesday, gives Day One exclusive rights to Sprint’s vaccinia-related kinase 1 (VRK1) project, a synthetic lethal target that’s associated with adult and pediatric cancers when overexpressed. In addition to receiving $3 million upfront, Sprint stands to gain an additional $313 million in milestone payments. VRK1 makes up a group of proteins that helps repair damaged DNA, maintains the cell life cycle and works with lysosome metabolism. Sprint lists the target as having the potential to enhance the body’s immune response, serving as a potential one-two punch with other immuno-oncology medicines.  The program is still in its infancy, however, with Day One co-founder and R&D chief Samuel Blackman, M.D., Ph.D., saying that the two companies will collaborate on the lead optimization process as the asset makes its way toward the clinic. Day One will reimburse Sprint for preclinical and development costs. It’s a relatively low-risk partnership for Day One, which is looking to bulk up the back end of its pipeline. The company had no preclinical assets in its pipeline before this deal. The pediatric-cancer-focused biotech has been on a roll with lead asset tovorafenib, a type II PAN-RAF inhibitor currently in three trials. Day One initiated submission of an approval application to the FDA this year in pediatric patients with relapsed or progressive low-grade glioma and is set to complete the filing by October.  Phase 2 data presented at the American Society of Clinical Oncology annual meeting this year found that tovorafenib elicited a 67% objective response though a median duration of response was not reached by the time of the Dec. 22, 2022, cutoff date. The median duration that patients were on treatment was just less than 11 months. Two days later, the company went on the fundraising prowl, closing a $172.5 million public offering June 12. Day One now has $442.9 million in cash on hand, enough to last into 2026.